Afleveringen
-
This episode provides a comprehensive review of methimazole for clinical endocrinologists, focusing on its historical context, pharmacological profile, and practical management strategies. We examine its mechanism of action, specifically the inhibition of thyroid peroxidase to block iodine organification and coupling, alongside its distinct pharmacokinetics that allow for once-daily dosing. The discussion covers precise titration strategies for mild to severe hyperthyroidism, monitoring protocols using thyroid function tests, and methods for tapering. Finally, we analyze the drug safety profile, differentiating minor cutaneous reactions from major idiosyncratic toxicities like agranulocytosis and cholestatic hepatotoxicity, while addressing first-trimester teratogenicity risks and pregnancy transitions.
-
This podcast episode provides an advanced clinical review of maternal thyroid dysfunction during gestation and the postpartum period tailored for practicing endocrinologists. The discussion analyzes the physiological stress test of pregnancy on maternal thyroid kinetics including the role of human chorionic gonadotropin and altered iodine clearance. Listeners will review the transition away from rigid trimester cutoffs to population based reference ranges alongside the challenges of standard free thyroxine immunoassays. The episode outlines precise levothyroxine titration protocols for overt and subclinical hypothyroidism stratified by antibody status and details the critical first trimester selection of propylthiouracil over methimazole to mitigate embryopathy risks. Finally the presentation covers the management of postpartum thyroiditis and the latest targeted case finding strategies for high risk patients.
-
Zijn er afleveringen die ontbreken?
-
This podcast episode covers the clinical landscape of immune checkpoint inhibitor induced endocrinopathies, focusing on mechanisms, diagnostic pathways, and long-term management strategies for practicing endocrinologists. Listeners will review the presentation of anti-CTLA-four induced hypophysitis, including its classic biphasic manifestation of pituitary swelling followed by central axes deficiencies. The episode contrasts this with the destructive, painless thyroiditis typically triggered by anti-PD-one and anti-PD-L-one agents, detailing the hyperacute shift from transient thyrotoxicosis to permanent hypothyroidism. Finally, the discussion addresses rapid beta-cell destruction leading to fulminant insulin-dependent diabetes, alongside rare toxicities like primary adrenalitis and hypoparathyroidism, emphasizing mandatory pre-cycle surveillance protocols.
-
This episode provides a high-level review of metformin, tracing its evolution from French lilac to the cornerstone of metabolic medicine. We explore its dual molecular mechanisms, balancing canonical AMPK-dependent pathways with non-canonical actions like mGPD inhibition and gut-brain axis modulation. The discussion reviews core clinical evidence from the UKPDS and DPP trials, examines its role in treating tissue-specific insulin resistance in polycystic ovary syndrome, and analyzes emerging data regarding mTOR inhibition in long COVID. Finally, we break down the pathophysiology of gastrointestinal distress, vitamin B12 deficiency, and the strict eGFR-based parameters required to mitigate the risk of lactic acidosis.
-
This episode reviews primary aldosteronism management, focusing on universal screening mandates and optimized pre analytic protocols to prevent false results. We break down the diagnostic workup, comparing immunoassay and mass spectrometry cutoffs, and discuss when to bypass confirmatory testing for direct lateralization. The discussion covers subtype classification using computed tomography and adrenal venous sampling, including exceptions for select young patients. Finally, we review therapeutic strategies, detailing unilateral laparoscopic adrenalectomy for lateralized disease and medical management with mineralocorticoid receptor antagonists, emphasizing the clinical importance of titrating medication doses to unmask suppressed renin levels and mitigate adverse long term cardiovascular tissue damage.
-
This podcast episode reviews the embryological, genetic, and pathophysiological architecture underlying primary aldosteronism. It traces how disrupted adrenocortical cellular migration and channelopathies in the zona glomerulosa drive autonomous mineralocorticoid excess. Listeners will explore the divergent molecular genetics distinguishing aldosterone-producing adenomas from idiopathic adrenal hyperplasia, highlighting somatic mutations in KCNJ5, CACNA1D, and ATP1A1. The discussion evaluates the four types of familial hyperaldosteronism, detailing the chimeric gene formation in type one and germline mutations in types two through four. Finally, the episode connects these molecular mechanisms to clinical findings, including the aldosterone escape phenomenon and postural diagnostic logic.
-
This episode explores the distinct pathophysiology, diagnosis, and management of age-related osteoporosis, focusing on cellular mechanisms like osteoblast senescence, inflammaging, and altered RANK-ligand signaling that drive cortical and trabecular decay. The discussion highlights the clinical challenges of secondary hyperparathyroidism, somatopause, and multi-axial hormonal declines in patients over age seventy. Listeners will gain insights into accurately interpreting DXA scores amid degenerative spinal changes, utilizing the FRAX tool, and ruling out secondary causes like multiple myeloma. Finally, the podcast outlines sequential therapeutic strategies, detailing the nuances of long-term bisphosphonate use, denosumab rebound risks, and initiating anabolic agents like romosozumab.
-
This episode details the dual pathogenesis and structured management of empty sella syndrome, focusing on primary forms driven by diaphragma sellae incompetence and chronic intracranial hypertension, alongside secondary forms resulting from adenoma regression, apoplexy, or hypophysitis. The discussion outlines a rigorous diagnostic framework prioritizing comprehensive hormonal screening, emphasizing early central adrenal axis assessment to mitigate life threatening crises before addressing thyroid and gonadal deficiencies. Additionally, the episode highlights critical neuroimaging markers including the infundibulum sign to exclude mass lesions, while establishing clear criteria for ophthalmologic and lumbar puncture workups to detect comorbid idiopathic intracranial hypertension in high risk patients.
-
This episode delivers a high-level briefing on the shifting paradigm in lipid management, bridging the 2026 American Heart Association and 2025 American Association of Clinical Endocrinology guidelines. We analyze the transition from percentage-based reductions to strict, risk-stratified absolute targets for low-density lipoprotein cholesterol, apolipoprotein B, and non-high-density lipoprotein cholesterol. The discussion details practical implementation of the novel PREVENT risk calculator, universal lipoprotein a screening thresholds, and advanced coronary artery calcium scoring for risk reclassification. Finally, we map out the mandated pharmacological escalation pathway, covering statins, ezetimibe, PCSK9 inhibitors, inclisiran, bempedoic acid, and targeted hypertriglyceridemia interventions.
-
In this episode, we unpack the endocrine drivers behind telogen effluvium, exploring how hormonal and metabolic shifts disrupt normal hair follicle kinetics. We review the cellular mechanisms forcing active anagen follicles into premature catagen and telogen phases, causing diffuse shedding months after the initial insult. The discussion focuses on differentiating thyroid dysfunction and postpartum estrogen drops from systemic stressors like iron and vitamin D deficiencies. Finally, we outline a targeted diagnostic laboratory evaluation for endocrinologists, detail key bedside maneuvers like the hair pull test, and provide evidence-based strategies to correct underlying metabolic imbalances and manage chronic shedding.
-
This episode explores the biochemical foundations of lipid metabolism, detailing the transition from dietary lipid processing to intravascular remodeling and intracellular utilization. We trace the exogenous and endogenous lipoprotein pathways, emphasizing the critical roles of apolipoproteins like B48, B100, CII, and E, alongside key enzymes including lipoprotein lipase and hepatic lipase. The discussion highlights low-density lipoprotein receptor regulation via SREBP2 and PCSK9, as well as the mechanisms governing reverse cholesterol transport mediated by HDL. Finally, we analyze the metabolic balancing act between de novo lipogenesis and beta-oxidation, concluding with an examination of how endocrine dysregulation in diabetes, hypothyroidism, Cushing syndrome, and acromegaly alters lipid homeostasis.
-
This podcast episode covers the classification, pathophysiology, diagnostic evaluation, and management of non-autoimmune thyroiditis, differentiating these distinct inflammatory disorders from autoimmune etiologies. Designed for endocrinologists, the discussion reviews subacute granulomatous, acute suppurative, Riedel, drug-induced, and radiation thyroiditis. Listeners will review characteristic clinical features, including painful presentations, stony-hard masses, and silent destructive phases. The episode highlights essential diagnostic tools, such as radioactive iodine uptake scans and ultrasonography, alongside phase-specific laboratory findings. Finally, the audio addresses targeted therapeutic strategies, spanning anti-inflammatory tapers, empiric antibiotics, surgical drainage, and advanced immunomodulatory treatments for fibroinflammatory disease.
-
This podcast episode covers the ongoing clinical paradigm shift in polycystic ovary syndrome, focusing on the proposed name change to polymorphic metabolic and ovarian syndrome to better reflect its multi-system nature. The discussion details the core pathophysiological drivers of the disorder, including accelerated hypothalamic gonadotropin-releasing hormone pulsatility, elevated luteinizing hormone to follicle-stimulating hormone ratios, intraovarian hyperandrogenism, and post-receptor insulin resistance. Clinicians will review the four distinct Rotterdam phenotypes, exploring how classic hyperandrogenic subtypes differ metabolically from non-hyperandrogenic variants, alongside a strategic diagnostic framework to differentiate true syndrome subtypes from critical adrenal or neoplastic mimics.
-
This podcast episode delivers a comprehensive clinical review of polycystic ovary syndrome, emphasizing its modern transition to polyendocrine metabolic ovarian syndrome. Listeners will explore the foundational pathophysiology of the disorder, focusing on gonadotropin dysregulation, intraovarian hyperandrogenism, and tissue-specific insulin resistance. The discussion provides evidence-based strategies for menstrual cycle control and endometrial protection using combined oral contraceptives and intrauterine systems. Additionally, the episode outlines first-line ovulation induction utilizing letrozole, the management of cutaneous hyperandrogenism with anti-androgens, and essential screening protocols to mitigate lifelong cardiometabolic and type two diabetes risks in this patient population.
-
This podcast episode delivers an exhaustive review of the diagnostic, phenotypic, and cardiometabolic framework of polycystic ovary syndrome, emphasizing strict adherence to the Rotterdam consensus criteria. Listeners will explore the specific phenotypic demarcations from classic high-risk metabolic subtypes to milder non-androgenic profiles, paired with a strategic four-step protocol to isolate the condition from clinical mimics like non-classic congenital adrenal hyperplasia and androgen-secreting tumors. The discussion details the post-receptor insulin signaling defects driving tissue-specific insulin resistance, the clinical superiority of the dynamic oral glucose tolerance test, and surveillance mandates for atherogenic dyslipidemia, metabolic syndrome, and steatotic liver disease.
-
This episode goes into the mechanisms of hyperparathyroidism-associated osteoporosis and bone loss.
-
Methimazole-induced cutaneous eruptions represent the most frequent side effect of thionamide therapy, ranging from minor rashes to life-threatening systemic syndromes. These reactions occur when the drug acts as a hapten, binding to proteins to trigger complex immune responses involving T-cell activation or antibody-mediated damage. While genetic factors and higher dosages increase susceptibility, clinicians must distinguish between mild cases manageable with antihistamines and severe reactions requiring immediate drug cessation. Because of the high risk of immunologic cross-reactivity between different thionamides, switching medications is often discouraged in favor of alternative treatments. For patients who cannot tolerate the drug, management shifts toward definitive solutions like radioactive iodine or surgical thyroid removal to control thyroid dysfunction safely.
-
This episode goes into the details of post-menopausal osteoporosis and how estrogen deficiency leads to reduced bone strength.
-
This episode takes a deep dive into glucocorticoid-induced osteoporosis and how steroids can drastically reduce bone strength, even for a short duration of therapy.
-
This episode describes the procedure and pitfalls of AVS (everyone’s favorite test)
Core AVS Indices and Interpretation
Adrenal venous sampling relies on three sequential biochemical indices to determine whether primary aldosteronism is unilateral or bilateral.
The first step calculates the Selectivity Index to confirm that the catheter tip was positioned correctly inside the adrenal lumen rather than a surrounding vessel. The index is determined by dividing the adrenal vein cortisol concentration by the peripheral vein cortisol concentration. Under unstimulated baseline conditions, a ratio greater than 2.0 verifies successful cannulation, whereas an ACTH-stimulated protocol requires a ratio greater than 5.0 due to increased cortical hormone output. If a sample fails to meet these specific thresholds, the blood is considered contaminated with peripheral circulation, rendering all subsequent calculations invalid and uninterpretable.
Once bilateral selectivity is confirmed, the Lateralization Index determines the source of aldosterone overproduction. The raw aldosterone concentration from each side is divided by its matching cortisol concentration to correct for asymmetrical blood flow and dilutional differences between the left and right adrenal veins. The final index is calculated by dividing the corrected ratio of the dominant high-secreting side by the corrected ratio of the non-dominant low-secreting side. An unstimulated ratio greater than 2.0 to 3.0 or an ACTH-stimulated ratio greater than 4.0 confirms unilateral disease, identifying the patient as a candidate for surgical adrenalectomy.
The Contralateral Suppression Index evaluates whether the unaffected, non-dominant gland is appropriately down-regulated by systemic feedback loops. It is calculated by dividing the corrected aldosterone-to-cortisol ratio of the non-dominant adrenal vein by the aldosterone-to-cortisol ratio of a peripheral vein. A ratio less than 1.0 confirms true physiological suppression, showing that the normal gland has gone dormant in response to the low-renin state caused by the contralateral tumor. If the index is 1.0 or greater, the non-dominant gland is actively manufacturing aldosterone independently, which strongly signals underlying bilateral hyperplasia despite a borderline lateralization index.
Autonomous cortisol secretion from an adrenal mass creates severe diagnostic pitfalls when evaluating primary aldosteronism via adrenal venous sampling. The excess cortisol triggers negative feedback on the hypothalamus and pituitary gland, downregulating adrenocorticotropic hormone (ACTH) secretion. Deprived of ACTH, the normal contralateral adrenal gland suppresses its own cortisol output. During an unstimulated procedure, this drop in cortisol falsely deflates the normal side's Selectivity Index, erroneously suggesting a catheter placement failure. Furthermore, using this artificially low cortisol level as a denominator falsely inflates the non-dominant side's corrected aldosterone ratio. This mathematical artifact can completely mask a true unilateral tumor or turn a bilateral hyperplasia case into a false unilateral diagnosis, risking an inappropriate or failed surgery.
Exogenous ACTH stimulation overcomes these pitfalls by directly binding to melanocortin 2 receptors on both glands. This pharmacological intervention overrides central pituitary suppression and forces the dormant, healthy gland to resume high-volume cortisol output, restoring a symmetrical biochemical baseline. However, ACTH can hyper-stimulate aldosterone secretion in adenomas that overexpress ACTH receptors, which alters standard lateralization index cutoffs. Measuring plasma free metanephrines provides an even better alternative for verifying selectivity because these medullary markers bypass the cortical steroid pathways entirely, remaining completely unaffected by cortisol autonomy or central pituitary feedback loops.
- Laat meer zien
